PHARMACY

Sandoz U.S. to pay $265 million in exchange for full release of all claims by the class.

The on-body device delivers Udenyca, a biosimilar pegfilgrastim administered the day after chemotherapy to decrease the incidence of infection as manifested by febrile neutropenia.

This screening broadens the Signify Health range of in-home services designed to support earlier detection, diagnosis and management of heart arrhythmias.

The study reveals the impact of a dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability.

Opill is expected to be available at major retailers and pharmacies nationwide by about the end of March or early April, according to a report.

Sandoz is closing the Fougera manufacturing and packaging facilities located in Melville and Hicksville on Long Island, N.Y.

An NACDS letter to President Biden urges Executive Branch action and support of immediate Congressional action on PBM reforms.

Point-of-care testing services enhance patient care, support pharmacy revenue.